RxDoctor Payments Data

Patrick Dorvilus, MD

Gastroenterology · Statesboro, GANPI 1144222456

Payments from drug & device makers

$4,609in general payments, 2019–2025

Across 242 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Romark Laboratories, LC$540
  • QOL Medical, LLC$496
  • Ardelyx, Inc.$494
  • Boston Scientific$202
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$210%
  • Food & beverage$4,588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,609 in reported general payments places this provider in the 50th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$69,996
Medicare patients
238
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbsrelaTenapanor Hcl53$104,191
LinzessLinaclotide106$65,052
CreonLipase/Protease/Amylase24$59,014
Nitazoxanide15$42,130
ZenpepLipase/Protease/Amylase16$36,338
TrulancePlecanatide13$8,449
Budesonide DrBudesonide18$2,604
Colestipol Hcl24$2,180
Sucralfate24$2,148
Lubiprostone26$2,104
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates31$2,092
Mesalamine ErMesalamine17$1,776
Scopolamine11$1,774
Famotidine134$1,462
Ondansetron OdtOndansetron32$1,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,520$124,066130 claims
Ardelyx, Inc.Ibsrela$494$104,19153 claims
Aimmune Therapeutics, Inc.Zenpep$104$36,33816 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$192$8,44913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →